Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
====================================================================================================================================================================================================================================

* Julia Katharina Schwarze
* Jens Tijtgat
* Gil Awada
* Louise Cras
* Angela Vasaturo
* Christopher Bagnall
* Ramses Forsyth
* Inès Dufait
* Sandra Tuyaerts
* Ivan Van Riet
* Bart Neyns